Antibody Drug Conjugates present a unique set of challenges for developing companies. The competition is fierce. The development is complex. Their structural exceptionality requires expertise in a number of different technologies for small and large molecules as well as analytical methods.
Sourcing out various stages of the supply chain has become almost unavoidable. Instead of using a variety of contracted researchers and manufacturers – why not simplify the process and minimize your number of partners?
The new joined competencies of MilliporeSigma help you overcome this multitude of challenges. We offer a comprehensive service portfolio that uniquely combines the crucial steps of your developmental process: mAb solutions, linker, payload and the final conjugation – all from a single source.